Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PPARG | P37231 | 5/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661382 | 0.83 | CYP1A2 (0.59) | MMECYP1A2PPARGEPHX2PPARA | |
| SCHEMBL3876493 | 0.83 | CYP1A2 (0.59) | MMECYP1A2PPARGEPHX2PPARA | |
| SCHEMBL6379983 | 0.83 | CYP1A2 (0.59) | MMECYP1A2PPARGEPHX2PPARA | |
| SCHEMBL11529738 | 0.83 | CYP1A2 (0.59) | CYP1A2PPARGEPHX2PPARAPPARD | |
| SCHEMBL265063 | 0.82 | CYP1A2 (0.83) | MMECYP1A2PPARGPPARAPPARD | |
| SCHEMBL265514 | 0.82 | CYP1A2 (0.83) | MMECYP1A2PPARGPPARAPPARD | |
| SCHEMBL491524 | 0.82 | CYP1A2 (0.83) | MMECYP1A2PPARGPPARAPPARD | |
| SCHEMBL8646633 | 0.82 | MMP2 (0.48) | MMEPPARGPPARAPPARD | |
| SCHEMBL17693395 | 0.81 | CPA1 (0.70) | MMECYP1A2PPARGEPHX2PPARA | |
| SCHEMBL5378074 | 0.81 | CYP1A2 (0.57) | CYP1A2PPARGEPHX2PPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| WO-2022015938-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022015977-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| US-9732029-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9725402-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3067352-A2 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | Cardioxyl Pharmaceuticals Inc. (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2278975-B1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160052862-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20140336137-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS, INC. | 2014-11-13 | — | — | US | disclosed |
| US-8791134-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8318705-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2278975-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | Cardioxyl Pharmaceuticals Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009137717-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | CARDIOXYL PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | EVOTEC LTD. (GB) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052862-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | MME 1708/4885CYP1A2 2023/4885PPARG 1056/4885 |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MME 3285/4885CYP1A2 4719/4885PPARG 1483/4885 |
| US-20140336137-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | MME 1708/4885CYP1A2 2023/4885PPARG 1056/4885 |
| US-20090281062-A1 | NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF | NOXO1, TNNI3, HAO2 | MME 1708/4885CYP1A2 2023/4885PPARG 1056/4885 |
| US-20130045951-A1 | Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof | NOXO1, TNNI3, HAO2 | MME 1708/4885CYP1A2 2023/4885PPARG 1056/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MME 3336/4885CYP1A2 4727/4885PPARG 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.